BioArctic Initiates Dosing in Early Stage Parkinson’s Trial With Exidavnemab
BioArctic AB (publ), a Swedish biotech firm focused on research, has revealed the commencement of patient dosing with their experimental drug, exidavnemab, in the phase 2a EXIST trial dedicated to those battling Parkinson’s disease. This drug is a monoclonal antibody […]
BioArctic Initiates Dosing in Early Stage Parkinson’s Trial With Exidavnemab Read More »